Advertisement

Supportive Care in Cancer

, Volume 20, Issue 5, pp 951–955 | Cite as

Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin

  • Kenichiro Nagata
  • Nobuaki EgashiraEmail author
  • Takaaki Yamada
  • Hiroyuki Watanabe
  • Yui Yamauchi
  • Ryozo Oishi
Original Article

Abstract

Purpose

Epirubicin is an antitumor drug, particularly used in the treatment of the breast cancer. The peripheral intravenous infusion of epirubicin frequently causes venous irritation such as, erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the epirubicin-induced venous irritation and to establish a suitable administration method of epirubicin.

Methods

The phlebitis scores (Visual Infusion Phlebitis score) were evaluated retrospectively using the collected nursing record. We analyzed the risk factor associated with venous irritation in 97 patients administered with epirubicin from December 2004 to September 2008. We subsequently changed the regimen of epirubicin and examined the incidence of venous irritation in 26 patients administered with epirubicin from August 2009 to March 2010.

Results

The phlebitis scores were significantly higher in the patients treated with ready-to-use solution compared with lyophilized powder (P = 0.04). Based on this result, we switched the formulation of epirubicin to lyophilized powder. After the intervention, the phlebitis scores were significantly decreased (P = 0.003). An ordinal logistic regression analysis revealed that use of ready-to-use solution was a significant predictor for venous irritation (odds ratio = 3.70; 95%, confidence intervals, 1.29–11.45; P = 0.02).

Conclusions

The use of ready-to-use solution was a risk factor for epirubicin-induced venous irritation. The change of formulation by pharmacist intervention decreased the risk of venous irritation.

Keywords

Epirubicin Venous irritation Phlebitis Pharmacist intervention 

Notes

Conflict of interest

None.

References

  1. 1.
    Glück S (2005) Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10:780–791PubMedCrossRefGoogle Scholar
  2. 2.
    Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4:425–439PubMedGoogle Scholar
  3. 3.
    Suga Y, Kumazaki M, Nishigami J et al (2009) Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation. Gan To Kagaku Ryoho 36:93–96PubMedGoogle Scholar
  4. 4.
    Jackson A (1998) Infection control–a battle in vein: infusion phlebitis. Nurs Times 94:68–71PubMedGoogle Scholar
  5. 5.
    Kuwahara T, Asanami S, Kawauchi Y et al (1999) Experimental infusion phlebitis: tolerance pH of peripheral vein. J Toxicol Sci 24:113–121PubMedCrossRefGoogle Scholar
  6. 6.
    Anami S, Masuda N, Nishikata M et al (2006) Factors associated with phlebitis and venous pain due to intravenous injection of epirubicin hydrochloride. Jpn J Pharm Health Care Sci 32:1105–1110CrossRefGoogle Scholar
  7. 7.
    Sugimoto M, Matsui M, Harada M et al (2009) Prevention of venous pain and phlebitis caused by epirubicin hydrochloride. Gan To Kagaku Ryoho 36:969–974PubMedGoogle Scholar
  8. 8.
    Polovich M, White JM, Kelleher LO (2005) Chemotherapy and Biotherapy Guideline and Recommendation for Practice. 2nd edn. Pittsburgh, PAGoogle Scholar
  9. 9.
    Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675PubMedCrossRefGoogle Scholar
  10. 10.
    Beckers MM, Ruven HJ, Seldenrijk CA et al (2010) Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res 125:318–321PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kenichiro Nagata
    • 1
  • Nobuaki Egashira
    • 1
    Email author
  • Takaaki Yamada
    • 1
  • Hiroyuki Watanabe
    • 1
  • Yui Yamauchi
    • 1
  • Ryozo Oishi
    • 1
  1. 1.Department of PharmacyKyushu University HospitalFukuokaJapan

Personalised recommendations